Greenwich LifeSciences, Inc. (Nasdaq: GLSI) stock jumped vigorously in the post-market trading hours, as the shares jumped 31.75% to reach $75.23 following, a clinical-stage biotech corporation focusing on improving GP2 and immunotherapy to reduce breast cancer infections in patients that have already undergone surgery, revealed the publishing of a poster for the GP2 Phase IIb clinical trial final efficacy study. An audio track giving an outline was also documented by the CEO of Greenwich LifeSciences, Snehal Patel. It is available to view on the organization’s website and the conference website for members.

The poster illustrates the final 5-year follow-up curves of disease-free survival analyzing the decline of breast cancer recurrence for patients in both HER2/neu 3+ (Figure 1) and HER2/neu 1-2+ (Figure 2) cohorts, comprising demographics (Table 1) for cancer level, hormone receptor status, node status, and previous chemotherapy, radiation, endocrine therapy, or trastuzumab treatment (Herceptin).